BREAK-3 study of Tafinlar shows 45% of patients still alive after 2 years with Melanoma - GSK

GSK announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant Metastatic Melanoma. These results, which include new survival data, showed 45 per cent of patients treated with dabrafenib were still alive at two years. The data were presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid.

Analysis of the study�s primary endpoint, progression free survival (PFS), was reported in 2012. The latest results relate to a secondary endpoint from this study, with a final analysis of the overall survival (OS) endpoint expected in 2016. 45 per cent of patients treated with dabrafenib only, were alive at two years compared to 32 per cent of patients who began treatment with dacarbazine (DTIC). 59 per cent of patients on DTIC treatment whose disease progressed subsequently received dabrafenib treatment and are included in the DTIC control arm results.